and a less than expected guidance for Opzelura. On the other hand, Citi analyst David Lebowitz adjusted the price target on Incyte shares to $88 from the previous $97 while retaining a Buy rating.

Incyte's Phase 3 TRuE-PN trials show ruxolitinib cream improves itch relief in prurigo nodularis, though TRuE-PN2's primary ...

Citi keeps a Buy rating on Incyte (INCY) with an $88 price target after the company presented data from its pivotal Phase 3 TRuE-PN1 trial ...

Opzelura is a topical version of Incyte's oral drug Jakafi/Jakavi, which is FDA approved for myelofibrosis, polycythaemia vera and graft-versus-host-disease, and has been billed as a major growth ...

Opzelura (ruxolitinib) is now the first alternative to steroid drugs for vitiligo, a chronic autoimmune disease that causes depigmentation of skin and affects around 1.5 million people in the US.

Digging deeper into the positive TRuE-PN1 results, twice daily Opzelura—also known as ruxolitinib cream 1.5%—helped 44.6% of adults with PN achieve a four-point or greater improvement from ...

OPZELURA (ruxolitinib cream) has shown strong market growth, driven by increasing adoption in dermatological conditions like vitiligo and atopic dermatitis. Its unique positioning as the first FDA ...